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Abstract
Achieving a theoretical foundation for malaria elimination will require a detailed understanding of the quantitative
relationships between patient treatment-seeking behavior, treatment coverage, and the effects of curative therapies that
also block Plasmodium parasite transmission to mosquito vectors. Here, we report a mechanistic, within-host mathematical
model that uses pharmacokinetic (PK) and pharmacodynamic (PD) data to simulate the effects of artemisinin-based
combination therapies (ACTs) on Plasmodium falciparum transmission. To contextualize this model, we created a set of
global maps of the fold reductions that would be necessary to reduce the malaria RC (i.e. its basic reproductive number
under control) to below 1 and thus interrupt transmission. This modeling was applied to low-transmission settings, defined
as having a R0,10 based on 2010 data. Our modeling predicts that treating 93–98% of symptomatic infections with an ACT
within five days of fever onset would interrupt malaria transmission for ,91% of the at-risk population of Southeast Asia
and ,74% of the global at-risk population, and lead these populations towards malaria elimination. This level of treatment
coverage corresponds to an estimated 81–85% of all infected individuals in these settings. At this coverage level with ACTs,
the addition of the gametocytocidal agent primaquine affords no major gains in transmission reduction. Indeed, we
estimate that it would require switching,180 people from ACTs to ACTs plus primaquine to achieve the same transmission
reduction as switching a single individual from untreated to treated with ACTs. Our model thus predicts that the addition of
gametocytocidal drugs to treatment regimens provides very small population-wide benefits and that the focus of control
efforts in Southeast Asia should be on increasing prompt ACT coverage. Prospects for elimination in much of Sub-Saharan
Africa appear far less favorable currently, due to high rates of infection and less frequent and less rapid treatment.
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Introduction
Plasmodium falciparum, the most virulent of the Plasmodium species
that cause malaria in humans, is responsible for hundreds of
millions of cases per year [1]. The number of fatal outcomes is a
matter of considerable debate, with estimates for 2010 ranging
from 655,000 to 1,238,000 [2,3]. Studies nonetheless agree that
overall levels of morbidity and mortality have declined over the
past decade, due at least in part to the worldwide scaling up of
insecticide-treated bed nets and the use of artemisinin-based
combination therapies (ACTs). ACTs, which pair fast-acting short-
lived artemisinin derivatives with longer-lasting partner drugs, are
now the first-line antimalarial drugs in almost the entire malaria-
endemic world [4,5].
Public health and malaria infection experts are increasingly
promoting the goal of malaria elimination in areas of low
transmission [6,7] while planning ways to achieve significant
reductions in higher-transmission areas [8,9]. Major obstacles,
however, stand in the way. These include insecticide and drug
resistance [10,11], under-developed health care systems, shifting
public funding priorities, donor fatigue [6], malaria importation
[12] and economic constraints [13]. The complex life cycle of P.
falciparum also presents unique challenges [14]. P. falciparum stages
differ markedly in their levels of metabolic activity, within-host
locations, and susceptibilities to antimalarials. Mathematical
modeling can help guide elimination efforts by providing
quantitative predictions to assess the feasibility of different
intervention and control strategies [15–18].
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ACTs and other antimalarial drugs reduce transmission in three
ways: by killing the disease-causing asexual blood stages and thus
preventing continued production of the intra-erythrocytic sexual
gametocyte forms; by killing existing gametocytes and reducing or
preventing onward transmission to the mosquito (thereby reducing
parasite oocyst numbers in mosquito midguts); and by post-
treatment drug prophylaxis wherein residual drug levels can
protect against new infections [19]. Here we utilize mathematical
modeling to quantify how ACTs reduce malaria transmission, with
or without late-stage gametocytocidal agents such as primaquine
(PQ) or methylene blue. These agents are receiving considerable
interest within the malaria community as to how their action
might be leveraged to help interrupt parasite transmission [20–22].
Here, we report outputs from our within-host model of P.
falciparum infection and transmission, and overlay these findings
onto geospatial maps of malaria endemicity in order to predict the
benefits of extended coverage of infected individuals and
incorporation of transmission-blocking agents into current ACT
regimens. In low-transmission settings we predict that if at least
93–98% of all symptomatic infections, corresponding to an
estimated 81–85% of all infected individuals, were treated within
five days of first fever, then the RC could be reduced to below one
and malaria would progress towards elimination in regions
harboring over ,91% of at-risk populations in Southeast Asia
and ,74% of the global at-risk population. Our findings suggest
that increasing treatment coverage with ACTs would be more
effective than adding additional transmission-blocking agents in
driving towards the goal of malaria elimination in Southeast Asia.
Results
A within-host model to predict the effects of drug
treatment on reducing malaria transmission
We used our recently developed within-host model of the
progression of P. falciparum infection [23] to simulate the densities
of asexual blood stage parasites and gametocytes in a population of
individuals with no acquired immunity to malaria. The variability
in densities among individuals was matched to the variability
observed in malaria therapy studies, in which syphilitic individuals
with no history of malaria infection were infected with P. falciparum
to induce a fever and clear the syphilis infection [23]. Of note, our
model incorporates three different types of antimalarial immunity:
an innate response that establishes an upper limit for parasite
density; a PfEMP1 variant-specific response that regulates short-
term periodic oscillations in density; and a variant-transcending
response that causes a steady log-linear decrease in density over
time, clearing the infection [23]. In our simulations, these
responses were calibrated such that the infection dynamics
matched those of experimental challenge volunteers who had no
previous malarial infections, i.e., we assumed that individuals
either had no prior episode of malaria or had acquired malaria so
long ago that their responses were equivalent to that of individuals
without prior infections. Further, we simulated only single
infections, i.e. we did not simulate infections that overlapped in
time.
Figure 1 illustrates six runs from our within-host infection
model; untreated individuals are denoted by ‘Untreated’ or ‘U’.
Figure 1A shows the log10 parasitized red blood cells (PRBC) per
mL, while Figure 1B depicts the daily gametocytemias over time,
which are typically two logs lower for untreated individuals. The
Figure 1A inset illustrates the asexual densities for the first 50
days post emergence of parasites into the bloodstream; colored
triangles illustrate the onset of first fever [23]. Once the daily
gametocytemias were simulated, a gametocyte density-to-infectiv-
ity relationship was utilized to translate these values into predicted
infectiousness to mosquitoes over time. Figure 1C illustrates the
predicted human-to-mosquito infectivity for each of the three
untreated individuals (U) using the Jeffery-Eyles (JE) relationship
between gametocyte densities and infectivity [23].
As described in detail below, we then incorporated the effects of
drug treatment into our within-host model to illustrate how this
modeled treatment affects malaria transmission. Figure 1 in-
cludes the results of a hypothetical drug treatment on three
individuals infected with P. falciparum; treated individuals are
denoted by ‘Treated’ or ‘T’. As with the untreated cases,
Figure 1A shows the asexual parasite densities in log10 PRBC/
mL, while Figs. 1B and 1C depict the daily gametocytemias and
human-to-mosquito infectivities. Treatment was assumed to begin
4, 9 and 14 days after the onset of fever. The effects of drug
treatment can be seen immediately on the asexual blood stage
population, which showed a steep drop in numbers after dosing, as
well as the gametocytemias that were lower among the treated
individuals following treatment. To calculate the net infectivity of
individuals to mosquitoes, gametocytes densities were transformed
into infectivity probabilities, and the area under the infectivity
curve was derived (AUIC). This approach was previously used
with field data [24] to estimate onward infectivity following
treatment. In the case where drugs reduced oocyst numbers
independently of their effects against gametocytes, the gametocyte
density-to-infectivity relationships were adjusted in a drug-
dependent manner. Infectivities of treated patients (T) were of
relatively brief duration and had largely disappeared within 30
days (Figure 1C). This hypothetical example illustrates many of
the processes involved in modeling the effects of drugs on
transmission. Below we describe how we have used in vitro and
field data to parameterize the various components of drug activity
and predict the effects of various antimalarial therapies in real-
world settings.
Modeling drug effects against asexual blood stage P.
falciparum parasites
To model the effects of different drugs on asexual parasite
densities, we first modeled the within-host concentrations of the
partner drugs of two ACTs, artesunate+mefloquine (AM) and
artemether+lumefantrine (AL). AM is a frequently used first-line
therapy in parts of Southeast Asia [24], while AL has recently
become the most widely-used ACT worldwide [25]. Because we
calculated our asexual parasite densities daily, we did not model
the explicit concentrations of the artemisinin derivatives, as these
drugs have half-lives of 1 to 3 hr [4]. However, we did incorporate
their fast-acting PD potency on asexual blood stage parasite
densities [4]. As a point of reference, we also modeled the drug
Author Summary
We utilize a within-host mathematical model of malaria
transmission to predict the effects of antimalarial treat-
ment across the globe. We predict that areas containing
91% of the at-risk population of Southeast Asia can
achieve elimination if at least 93–98% of symptomatic
individuals are promptly treated with effective artemisinin-
based combination therapies (ACTs), based on assess-
ments of treatment and transmission levels as of 2010. The
benefit of attaining this level of coverage far outperforms
that of adding additional gametocyte-specific transmis-
sion-blocking drugs to current ACTs. We advocate for
elimination programs in Southeast Asia to focus on
maximizing ACT coverage.
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concentrations of chloroquine (CQ), the former first line therapy
that is highly active against asexual blood stages and has some
activity against very early stage gametocytes but is inactive against
mature gametocytes [21]. For lumefantrine (LMF) uptake and
clearance we used a two-compartment pharmacokinetic model
parameterized from field data; for mefloquine (MFQ) and CQ we
used two-compartment non-parametric models, also parameter-
ized from field data. Model equations, model parameters, and a
description of the model fitting to average concentrations as well as
population variation are detailed in Text S1. Notably, our study
assumed that individuals were fully compliant with treatment and
that parasites were sensitive to the various drug combinations. In
future work we hope to examine how differences in patient
compliance and parasite drug susceptibility impact transmission.
Figure 2 (panels A, C, E) illustrates the results of our PK
simulations for LMF, MFQ, and CQ, respectively. The black lines
indicate the median (LMF) or mean (MFQ, CQ) of the population
concentrations, while the blue lines indicate simulated individual
concentration profiles. Model outputs revealed wide variations in
concentrations within a population, due to differences in rates of
drug uptake and clearance. The number of concentrations
depicted in each panel corresponds to the number of patients in
each of the studies that provided data for model fitting. Of note,
LMF plasma concentrations achieved considerably higher levels
than the other two agents.
To simulate the effects of these drug concentrations against asexual
parasites, we first calculated hourly plasma and/or blood concentra-
tion levels from our PKmodeling.We then translated the hourly drug
concentrations into asexual activities, assuming that the dose-response
relationships could be modeled as Hill functions. These Hill functions
were parameterized from in vitro and field data (see the SI). The
asexual activities of drugs were quantified as 48-hour parasite
reduction ratios (PRRs), i.e., the fold decreases in parasite numbers
every 48 hr, corresponding to one cycle of intra-erythrocytic
development and reinvasion. Figure 2 (panels B, D, F) illustrates
the drug concentrations translated into these PRRs over time. To
calculate the asexual parasite densities in our model under the effects
of drugs for a generic day t, we took the densities from day t-1, applied
our within-host model to calculate densities on day t including both
the effects of parasite growth and host immune responses, then
multiplied densities by the square root of the mean 48-hour PRR for
drug concentrations during day t. The resulting density was then used
to calculate densities at t+1, and so on until the end of the simulation.
Regardless of the drug regimens simulated here, asexual
parasite densities fell rapidly when an individual was treated.
The PRRs nevertheless showed substantial differences between
drugs in later time periods following treatment. For example, the
LMF PPRs rapidly declined within 5–15 days of treatment,
whereas CQ took longer to decline while showing more
heterogeneity. MFQ was also heterogeneous but always showed
lower PPRs even at peak plasma concentrations. The maximal
PRRs, and the differential rates of absorption, clearance, and
volumes of drug distribution are described more fully in the SI.
Predicted effects of antimalarials on gametocyte
development and transmission
While effective drug treatment rapidly clears asexual blood
stage parasites, even successful regimens differ markedly in their
Figure 1. Illustration of asexual, gametocyte, and human-to-
mosquito infectivity model outputs. The P. falciparum infection
model was run six times to simulate three untreated individuals and
another three treated with a hypothetical antimalarial. (A) Individual
log10 asexual blood stage parasitemias as a function of the number of
days post emergence of parasites from the liver into the bloodstream.
The inset depicts the first 50 days of infection; the triangles above
indicate the first day of fever. In this example, three individuals were
assumed to seek treatment a variable number of days after the onset of
fever. The black line illustrates the approximate level of detectability by
microscopy (,10 parasitized red blood cells/mL). (B) Daily gametocy-
temias (sexual stage parasitemias) of the same six individuals. The
hypothetical drug treatment was assumed to target early stages of
gametocyte development more strongly than later stages. (C)
Estimated probability of human-to-mosquito parasite transmission for
treated (T) vs. untreated (U) individuals. Areas under the infectivity
curves (AUIC) are equivalent to the number of fully infectious days. Net
infectivity simulations yielded 1.0, 2.4, and 6.3 fully infectious days for
treated (T) and 67.7, 6.5, and 28.6 days for untreated (U) individuals,
respectively. The model outputs for untreated patients shown in panels
A–C were previously reported in [23] and are shown to compare with
our modeling of treated patients.
doi:10.1371/journal.pcbi.1003434.g001
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Figure 2. Modeled pharmacokinetic and pharmacodynamic profiles of lumefantrine (LMF), mefloquine (MFQ) and chloroquine (CQ)
against asexual blood stage parasites. (A) Modeled plasma concentrations of LMF. The wide variability in concentrations reflects individual
differences in absorption and clearance. The black line indicates population median drug concentrations. (B) Estimated parasite reduction ratios (PRR)
over a 48 hr blood stage cycle for LMF as a function of time post onset of treatment. PRR is the fold reduction in asexual parasite densities due to
drug action. PRR values were calculated from drug concentrations using a Hill function transformation. Each curve illustrates the PRR over time for a
simulated individual; the black line illustrates the PRR for population median drug concentrations. (C–D) Plasma concentrations for MFQ and
corresponding activities against asexual blood stage parasites. Drug concentrations reflect data from both plasma and whole blood studies. (E–F)
Modeled plasma concentrations of both CQ and its metabolite monodesethyl-chloroquine (mdCQ) are shown in turquoise; PRR against asexual blood
stages are in purple. All drug concentrations are in mg/ml.
doi:10.1371/journal.pcbi.1003434.g002
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effects on gametocytes. As gametocytes develop, they become
metabolically more inert, thus reducing the number of drug
targets available. Specifically, gametocytes mature over the
course of ,10–15 days through Stages I–V, with each stage
differing in metabolic activity and drug susceptibility [26]. Stages
I–IV are sequestered in the microvasculature, spleen or bone
marrow and are not present in the blood circulation. Only Stage
V gametocytes have matured to the point of releasing from
sequestered sites, thus becoming visible by blood smear. Here, we
simulated differential effects of drugs against each developmental
stage. This feature is novel to the literature so far as we know,
although a recent article did allow for a differential effect on non-
circulating vs. circulating gametocytes [27].
To parameterize the modeled effects of drugs on gametocytes,
we first conducted a literature review to examine the types of
datasets that could inform the model. There are few in vitro studies
that have measured the stage-specific effects of drugs on
gametocytes [21]; however, many field studies have examined
the clearance of gametocytes within a population after drug
treatment. These studies typically measured the proportion of
individuals who were gametocytemic by microscopy after treat-
ment (threshold for detection:,5–10 gametocytes per mL [28,29]).
Figure S1 illustrates the prevalence of gametocytes from field
studies of patients treated with a variety of antimalarials [28,30–
38]. The field studies are disaggregated by drug type: treatment
with SP [28,30,33]; CQ or amodiaquine (AQ) (sometimes in
combination with SP) [28,30–33]; various ACTs [28,30–32,34–
36,38]; or ACTs plus PQ [35,36,38]. The inter-study variability
observed in Figure S1 was likely due to a variety of factors,
including the levels of acquired immunity in the population, exact
timing of treatment, age of treated individuals, differences in
parasite biology, and drug treatment regimens.
These data were used to calibrate the gametocyte component of
our drug effects model. To generate a set of model outputs to
compare against field data, we simulated treating individuals with a
three-day course of AM and varied the assumed killing properties of
the two component drugs. We assumed that treatment started
relatively early in the infection, i.e., 5 days after first fever, in
agreement with field studies from Thailand and Indonesia [34,38].
Treatment timing will vary from place to place given the treatment-
seeking behaviors of the local population; if treatment is delayed
significantly beyond this point, the ability of drugs to reduce
transmission is likely to be diminished. We began our simulations
assuming that the treatment had no effect on gametocytes at all; we
called this therapy purely schizonticidal. We then increased the
simulated killing properties of the combination, assuming that the
components only killed early stages of gametocytes (e.g. as for CQ).
We gradually increased this presumed killing power against early
gametocytes (frommild to varying levels of moderate to strong, as in
Figure 3A): as the killing power increased, gametocyte prevalence
post-treatment decreased. We then assumed that the short-lived
component killed both early and late stage gametocytes, with a
larger effect on the former (e.g. as for an ACT). Finally, we
simulated adding a single dose of a third drug that killed both early
and late stage gametocytes, with varying levels of activity (e.g. as for
ACT+PQ). Additionally, we varied the timing of this third
component as this has been a topic of debate [39], by assuming
that treatment occurred either on the first day of ACT treatment,
denoted by ‘,day 0.’, or last day, denoted by ‘,day 2.’. Our
studies used the simulated prevalence of post-treatment gametocyte
positive individuals as the output to be compared against field data,
since this metric was most often tracked in the field.
Once the model outputs had been generated, these were
compared to field studies of drug treatments with similar activity
(see Figures S1, S2): the modeled schizonticidal treatment data
were compared to field trials with SP; mild to moderate
gametocytocidal outputs were compared to data from field trials
of CQ, CQ+SP or AQ+SP; strong gametocytocidal outputs were
compared to ACT clinical trials data, and the modeled triple-
combination data were compared to field data for ACTs+PQ. For
each drug activity type we then chose the sets of simulations that
most closely resembled the mean, maximum, and minimum of
observed responses to represent the effects of each class of drugs
against gametocytes. We also included some intermediate sets of
simulations for the sake of comparison. Figure S2 illustrates the
model outputs that best approximated the mean and observed
variation in the field data; all model means were from 1,000 runs
for each parameterization. We modeled the entire range of
observed variation in post-treatment gametocytemias to allow for
sensitivity and robustness analyses in our results. This ‘ensemble
modeling’ approach has been used previously to model the effects
of vaccines on malaria transmission [40] as well as within-host P.
falciparum dynamics [41].
Figure 3A illustrates the results of the gametocyte activity
model fitting. The untreated model gametocyte prevalence 5 days
after first fever is shown in black. The modeled post-treatment
gametocyte prevalence assuming a pure schizonticidal combina-
tion is shown in green. The four model parameterizations that best
correspond to the observed field patterns after CQ treatment are
labeled ‘CQ mild’, ‘CQ moderate 1’, ‘CQ moderate 2’, and ‘CQ
strong’, respectively (indicating increasing levels of activity against
very early stage gametocytes). The three model parameterizations
that best correspond to the ACT field patterns are labeled ‘ACT
mild’, ‘ACT moderate’, and ‘ACT strong’, respectively. The four
model parameterizations that correspond to the ACT+PQ field
studies are labeled ‘ACT+PQ moderate ,day 0.’, ‘ACT+PQ
moderate ,day 2.’, ‘ACT+PQ strong ,day 0.’, and ‘ACT+PQ
strong ,day 2.’; the bracketed number indicates the day on
which the simulated PQ component was administered, relative to
the other two drug components.
Once the gametocyte parameterizations were fitted for each
type of drug combination, we then transformed the daily
gametocytemias before and after treatment into predicted
infectivities to mosquitoes. These transformations utilized game-
tocyte density-to-infectivity relationships derived from mosquito
feeding studies, as described in [23]. We chose two transforma-
tions, one derived from studies of mosquito feeding on malaria
therapy patients with no prior history of malaria infection (‘Jeffery-
Eyles’ or JE) and the other derived from feeding studies conducted
in field trials in Africa (‘Carter & Graves’ or CG). In short, the JE
transformation assumes that 1) gametocytes appearing in the first
few days of infection are non-infectious (immature); 2) low density
gametocytemias are relatively non-infectious; 3) high density
infections are highly infectious. The CG relationship assumes that
1) gametocytes are immediately infectious; 2) low density
gametocytemias are relatively infectious; 3) high density infections
are not as infectious as for JE [23]. These two functions are
substantially different and represent some of the possible types of
density-to-infectivity relationships. Calculation using both rela-
tionships allows us to highlight where differences in density-to-
infectivity assumptions play an important role in interpreting
model outputs [23]. It was assumed for both parameterizations
that modeled gametocytemias were infectious at densities below
the level of detection by microscopy (,5–10 gametocytes per mL).
Our model is thus able to capture the effects of ‘submicroscopic’
infections [23,35,42]. However, as densities decrease, infectivity
decreases asymptotically toward 0 (see Figure 3 of [23]). As a
simplification we assumed that gametocyte densities below 2
Modeling Transmission Blocking and Malaria Elimination
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gametocytes per 3 mL were non-infectious (given the need for 2
gametocytes per mosquito bite that typically collects ,3 mL of
blood) [23].
Figure S3 illustrates the modeled gametocytemias of
Figure 3A transformed into probabilities of mosquito infection,
along with data from feeding studies in the field [28,30–33],
treatment with various ACTs [28,30–32,34–36,38], and treatment
with ACTs plus PQ [35,36,38]. Both the JE and CG transformed
probabilities are shown; the data transformed using the JE
assumptions are in bold. The coloring of modeled infectivity data
corresponds to that of Figure 3A. The field feeding study data
were disaggregated according to the same criteria as the
gametocyte clearance data.
Once the model gametocyte and infectivity parameters were
fitted to data, we then calculated the AUIC for each drug
parameterization [23]. Table 1 provides the unadjusted net
human-to-mosquito infectivity for each of the drug parameteriza-
tions in Figure 3A. All data are from the mean of 1,000 model
Figure 3. Modeled post-treatment gametocyte prevalence and treatment effect sizes. Treated and untreated malaria infections were
simulated using our within-host malaria infection model. Modeled treatments differed according to the assumed level of gametocyte killing. Model
treatment was assumed to start 5 days after the first onset of fever; all model outputs represent the mean of 1,000 runs. (A) The number of individuals
predicted to be gametocyte positive by microscopy (threshold 5 gametocytes per mL) was tracked over time. Untreated model outputs are shown in
black. Treatment was assumed to be a combination therapy with a short-lived component (active for 3 days) and a longer-lived component with the
pharmacokinetic profile of mefloquine. The green line illustrates the effects of treatment assuming no gametocytocidal activity (‘Schizonticide’). The
assumed gametocytocidal activity of each component was progressively increased and compared to field data to generate the rest of the curves,
each labeled with their corresponding antimalarial (chloroquine, CQ; artemisinin-based combination therapy, ACT; primaquine, PQ). The curves
labeled ‘ACT+PQ’ assumed the presence of a second short-lived partner that strongly killed both early and late stage gametocytes; the number
indicates the day on which the simulated PQ component was administered. (B) Total effect sizes (fold-reductions in transmission) for each of the
modeled drug parameterizations as a function of treatment coverage, including the oocidal effects of drugs, assuming net untreated infectivity of
30.5 days, and using the ‘Jeffery-Eyles’ density-to-infectivity parameterization for treated individuals (Table 2; [23]). Each drug class is depicted in a
different color. The variation in each class is due to the different simulated levels of gametocytocidal activity for that drug type. Each line within a
given drug class represents the result of 1,000 simulation runs; the black lines indicate the mean effect sizes for each class of drug. The horizontal line
illustrates a six-fold reduction in transmission. The dotted vertical lines indicate the levels of treatment coverage needed to reach a six-fold reduction
in total human-to-mosquito transmission for each drug class. The y-axis is in log-scale.
doi:10.1371/journal.pcbi.1003434.g003
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runs. To determine the transmission reduction achieved with each
treatment, we divided the untreated AUIC by the treated AUIC.
For example, to calculate the transmission reduction post-
treatment, we first took untreated individuals and calculated the
mean AUIC for 5 days after first fever until the end of simulation;
the mean untreated AUIC values were 31.8 for the JE
parameterization and 29.3 for the CG parameterization
(Table 1). The post-treatment net infectivities of treated
individuals, i.e. the treated AUIC values, were 0.70 for JE and
0.94 days for CG (Table 1). Mean fold reductions in transmission,
post ACT treatment, were then 47.1 and 32.4 for JE and CG
transformations, respectively (Table 1).
The quantity most relevant for control efforts is the total effect
size, i.e., the reduction in transmission that includes the period of
transmissibility before treatment. The longer that individuals wait
to be treated, the less the maximum effect size achievable, because
these individuals could transmit the parasite prior to treatment.
After adding pretreatment infectivity (0.03 or 3.06 infectious days
for JE and CG transformations respectively), the total mean fold-
reductions for ACTs were 45.3 and 8.1, respectively. For
ACT+PQ, total mean effect sizes were predicted to be 92.2 (JE)
and 8.9 (CG), respectively. The reason for the large differences
between these two transformations is how they incorporate pre-
treatment infectivity. Thus, pretreatment infectivity plays a major
role in the total effect size. For JE, gametocytes were assumed to be
non-infectious early in the course of an infection, thus pretreat-
ment infectivity was almost nonexistent and the effect size was
determined by post-treatment infectivity. In contrast, the CG
model assumed that gametocytes were infectious upon emergence,
thus pretreatment infectivity was relatively large compared to post-
treatment infectivity.
Purely schizonticidal treatments (with zero gametocytocidal
activity) were predicted to reduce post-treatment transmission 6.2
to 5.7 fold (JE and CG, respectively). Including pretreatment
infectivity, the mean effect size of a pure schizonticide was 6.2 and
3.9 (JE and CG, respectively). For CQ, which is moderately
gametocytocidal against stage I–II gametocytes, total effect sizes
were estimated to be 15.6 and 6.0 for the JE and CG
parameterizations, respectively. These findings highlight the
substantial benefit of drugs with more potent gametocytocidal
activity in reducing transmission.
Incorporating effects on mosquito-stage parasite
development
The fold reductions in Table 1 illustrate how antimalarials
reduce transmission assuming 100% treatment coverage. Howev-
er, these calculations do not incorporate the oocidal effects of some
antimalarials. Treatments that are also oocidal (such as SP, LMF,
and MFQ [42]) will have larger effect sizes than predicted in
Table 1 because of greater reductions in overall human-to-
mosquito transmission. To calibrate oocidal drug effects, we
compared unadjusted model-predicted infectivity and observed
field infectivity post-treatment (see Text S1 and Figure S3). For
our ACT model infectivity, at day 7 the feeding studies indicated
an infectiousness of approximately 2–3.5%, whereas the model
predicted 5–8% under the JE parameterization (see Figure S3C).
This small difference between model and field studies nearly
disappeared by day 14 (possibly because of a dose-response effect
of LMF on mosquito stage development). To incorporate oocidal
activity, we thus assumed that ACTs (AL or AM) reduced onward
infectivity by 50% compared to the mean values in Table 1.
Mean post-treatment infectivity values became 0.35 (JE) and 0.47
(CG) net infectious days while the total effect sizes became 83.7
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assumed importance of pretreatment infectivity played a crucial
role in determining the effect sizes of treatment when the oocidal
effects of treatment were included.
When examining the effects of ACTs plus PQ, our adjustment
for the oocidal effects of PQ was different than that for LMF or
MFQ, because PQ is active against mosquito stages for only a few
days after treatment, but reduces infectivity almost completely
during its period of activity [43,44]. If we assumed that infectivity
in the first three days post ACT+PQ treatment was zero, then the
net infectivity post-treatment was 0.19 (JE) and 0.30 (CG) and the
total mean effect sizes were 162.1 (JE) and 9.6 (CG), respectively.
Figure 3B illustrates the total effect sizes for each of the modeled
drug parameterizations as a function of treatment coverage,
including the oocidal effects of drugs from Table 2, assuming that
the mean period of infectivity in untreated individuals is 30.5 days
(mean untreated infectivity from Table 1) and assuming the JE
density-to-infectivity parameterization for treated individuals. Each
drug class is depicted in a different color with individual lines
showing simulation outputs assuming varying levels of gametocy-
tocidal activity (CQ: mild, moderate 1, moderate 2, strong); (ACT:
mild, moderate, strong); (ACT+PQ: moderate 0 days delay,
moderate 2 days delay, strong 0 days delay, strong 2 days delay).
The black lines clustered within each drug class indicate the mean
effect size across all simulations. The horizontal line illustrates a six-
fold reduction in transmission, a threshold discussed below. The
dotted vertical lines indicate the levels of treatment coverage needed
to reach the six-fold reduction in total human-to-mosquito
transmission for each drug class. The y-axis is in log-scale. This
figure graphically illustrates the importance of treatment coverage
in determining the effect size of a control program.
At 100% coverage (i.e. all infected individuals), the effect size of
ACTs is 87.3 (JE parameterization, Table 2), assuming untreated
infectivity is 30.5 days. However, this value drops quickly, yielding
16.3 at 95% coverage, 9.0 at 90% coverage, 4.8 at 80% coverage,
and 3.2 at 70% coverage. For ACT+PQ, the effect sizes are 162.1,
17.7, 9.4, 4.9, and 3.3 at 100%, 95%, 90%, 80%, and 70%
coverage, respectively. Treatment with ACTs exceeds a six-fold
reduction threshold at ,84.3% coverage of the total population,
whereas the ACT+PQ regimen exceeds a six-fold reduction at
,83.9% coverage of the total population.
Sensitivity analyses
The above effect sizes (and those in Figure 3) were calculated
assuming the untreated infectivity is 30.5 days (the mean of the JE
and CG parameterizations) and using the JE parameterization for
treated individuals. If we use the average of the JE and CG
parameterizations for treated individuals, and still assume that the
untreated net infectivity is 30.5 days, the pretreatment net
infectivity is 1.55 (average from Table 1), the post-treatment
net infectivity for ACTs is 0.41 (average from Table 2), and the
computed effect sizes of ACTs become 15.6 at 100% coverage, 9.0
at 95% treatment coverage, 6.3 at 90% treatment coverage, 4.0 at
80% coverage, and 2.9 at 70% coverage. Assuming a post-
treatment net infectivity of 0.245 for ACT+PQ (average from
Table 2), these values become 17.0, 9.4, 6.5, 4.0, and 2.9 at the
coverage levels listed above. Treatment with ACTs reaches a five-
fold reduction in transmission at 85.5% coverage of the total
population; with ACTs+PQ, the coverage level required is 85.0%.
Treatment with ACTs exceeds a six-fold reduction threshold at
89.1% coverage, whereas the ACT+PQ regimen exceeds a six-fold
reduction at 88.5% coverage. These outputs suggest a barely
detectable impact of adding PQ to ACTs in the context of
reducing transmission levels with these model assumptions.
Mapping of fold-reductions in transmission necessary for
malaria elimination
To contextualize the fold-reductions in transmission theoreti-
cally achievable with various treatments, we developed a set of
maps of the fold-reductions in malaria transmission necessary to
achieve elimination in low-transmission settings. These maps were
derived from the worldwide maps of the basic reproductive
number of malaria, R0 [45], assuming the malaria control
coverage of 2010 as the baseline. We can also consider these
maps as calculating the RC, i.e. the reproductive number under
control efforts, as of 2010, though here we use the terms R0 and RC
interchangeably. R0 is a threshold criterion for transmission: if
R0.1 over a given region, the disease will spread within this region
(unless there is significant migration), if R0,1, the disease will
disappear within this region (unless there is significant importa-
tion).
In brief, the R0 values described in [45] were developed by
regressing various malariometric data (such as elevation and
rainfall) on tens of thousands of parasite rate surveys and modeling
the spatio-temporal autocorrelation structure of the residual
variation. The regressions used were Bayesian and geostatistical,
producing a full Bayesian posterior distribution for the age-
standardized parasite rate at each pixel (with a per-pixel size of
565 km, i.e. 5 km2).
Table 2. Modeled net infectivities and effect sizes of antimalarial treatment (adjusted for oocidal effects).
ACT ACT+PQ









Net Infectivity (JE) 0.45 0.33 0.27 0.35 0.24 0.26 0.10 0.16 0.19
Net Infectivity (CG) 0.60 0.45 0.37 0.47 0.34 0.41 0.16 0.29 0.30
Fold-reduction (post-treatment, JE) 70.5 96.2 115.9 94.2 129.7 120.4 318.5 194.6 190.8
Fold-reduction (post-treatment, CG) 49.0 65.6 79.6 64.8 86.3 71.3 180.1 99.7 109.4
Effect size, JE 66.8 89.3 106.0 87.3 117.4 109.7 253.1 168.1 162.1
Effect size, CG 8.9 9.2 9.4 9.2 9.5 9.3 10.0 9.7 9.6
Abbreviations: JE, Jeffery-Eyles; CG, Carter & Graves; ACT, artemisinin-based combination therapy; PQ, primaquine. Net infectivity values indicate the mean number of
days that an individual is infectious for a mosquito vector, as explained in Table 1. Effect sizes illustrate the fold reductions in transmission for an ACT or ACT+PQ
treatment, modeled with distinct levels of gametocytocidal activity). The numbers in brackets for the ACT+PQ treatments indicate the treatment day on which the PQ
component was administered.
doi:10.1371/journal.pcbi.1003434.t002
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These worldwide maps of predicted parasite rates varied in
intensity from pixel to pixel, given different magnitudes of various
malaria covariates. By utilizing empirical and theoretical relation-
ships, the maps were combined with aspects of malaria that
remain constant over time and space to calculate R0. One such
malaria invariant is the net infectivity of infected humans to
mosquitoes, assuming no acquired immunity developed over the
course of repeated infections [23]. To calculate this invariant, we
used our within-host model of malaria transmission to simulate the
progression of infectivity in thousands of simulated individuals,
and then calculated the mean area under the human-to-mosquito
infectivity curves [23].
To achieve elimination in a given area, the fold-reduction in
transmission under control must be greater than or equal to the R0
[46]. Thus, we took the worldwide maps of R0 in [45] and
calculated the fold-reductions necessary over each pixel to reduce
the estimated RC to below 1. Our maps of the transmission
reductions include estimates of uncertainty inherited from the RC
posterior densities at each pixel. Table 3 summarizes these maps
by providing the number of people living in areas requiring ,2
fold reductions in transmission to interrupt transmission, as well as
2–5, 5–10, 10–20, 20–50, 50–100, and .100 fold reductions to
interrupt transmission. Table 3 calculates these necessary fold-
reductions with 75% confidence, i.e., our posterior estimates of RC
fall within the given regions with 75% confidence.
Because our within-host model simulates the progression of
infections for individuals with no prior history of malaria infection,
our modeling conclusions are most relevant for areas of low
transmission where individuals have accumulated little acquired
immunity from prior infections. We thus restricted our analyses to
areas with R0,10, which excludes the more endemic areas of
Africa and aligns with the transmission levels prevalent in
Southeast Asia. In terms of biting intensity, an R0 of 10 translates
to a yearly entomological inoculation rate of approximately 3
infectious bites per person per year, which would result in
approximately 1.5 infections every year [47]. This upper limit of
analysis can be compared with the intensity reported in an area of
‘low and seasonal’ transmission in Thailand, where individuals had
one infection every other year [34].
Figure 4 provides a worldwide map of the probabilities that
areas can interrupt malaria transmission (RC,1) assuming a five-
fold reduction in transmission. Areas with R0.10 are masked, as
these regions have such high transmission that our modeling
predictions are less relevant. Fold reductions were organized into 6
bins for clarity. Figure 5 shows these probabilities of interruption
for Southeast Asia, where transmission is generally much lower
than in Africa. Figures S4 and S5 present maps of the
probabilities of interrupting transmission assuming two- or ten-
fold reductions in transmission, respectively. These maps are
discussed below in the context of the reductions achievable with
antimalarial drugs.
Discussion
This study calculates the effects of antimalarial therapies on P.
falciparum transmission, using a within-host model of malaria
infection [23] and a PK/PD model parameterized from field
studies. The effects of drugs are modeled on both asexual and
sexual stages of parasite development under different assumptions
Table 3. Required effect size required to reduce RC below 1, worldwide and solely in Southeast Asia, stratified by populations at
risk.
Required effect size Population Population at risk (%)
Total population
(%)
Worldwide no risk 4,362,130,000 62.89%
,2 1,672,204,000 64.97% 24.11%
2–5 223,901,000 8.70% 3.23%
5–10 94,173,000 3.66% 1.36%
10–20 83,986,800 3.26% 1.21%
20–50 123,546,000 4.80% 1.78%
50–100 84,695,100 3.29% 1.22%
.100 291,346,000 11.32% 4.20%
Total population 6,935,981,900
Total pop at risk 2,573,851,900
Southeast Asia no risk 56,595,000 24.98%
,2 135,508,000 79.71% 59.80%
2–5 19,389,600 11.41% 8.56%
5–10 7,800,520 4.59% 3.44%
10–20 3,838,410 2.26% 1.69%
20–50 2,955,060 1.74% 1.30%
50–100 477,035 0.28% 0.21%
.100 39,566 0.02% 0.02%
Total population 226,603,191
Total pop at risk 170,008,191
Abbreviations: Southeast Asia is defined here as encompassing the countries Thailand, Myanmar, Laos, Vietnam, and Cambodia. Required effect size denotes the fold-
reduction in malaria transmission needed to interrupt transmission over the given population. Confidence of interruption is at the 75% level.
doi:10.1371/journal.pcbi.1003434.t003
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of gametocyte-to-infectivity relationship. We also generate global
maps of the fold reductions in malaria transmission, i.e. the effect
sizes, necessary to achieve elimination in regions of low endemicity
(defined as having local R0 values less than 10).
From our model outputs, we can generate three major
conclusions. First, the infectivity of individuals before treatment
plays a crucial role in determining effect size. If treatment is
delayed more than only a few days after the onset of fever, and
gametocytes are infectious during this period, then the effect sizes
achievable even with first-line ACT therapies plus the gametocy-
tocidal agent PQ are limited. Second, if we account for the effects that
the partner drugs LMF and MFQ exert upon mosquito stages of the
Figure 4. Worldwide map of the predicted probabilities that a five-fold effect size will interrupt malaria transmission. This map shows
the predicted probabilities that a five-fold reduction in transmission (‘five-fold effect size’) would interrupt malaria transmission over a given pixel.
Map pixel size is 5 km2. In order to interrupt malaria transmission in a given area, the basic reproductive number for malaria under control (RC) needs
to be reduced below 1. Probabilities for each pixel are calculated according to Bayesian posterior estimates of uncertainty [45]. Probabilities have
been binned into six categories for clarity. Areas with high transmission (defined as at last a 50% probability of R0.10) are masked because our
model results are applicable to regions of relatively lower transmission. Most of Sub-Saharan Africa is masked because of the very intense
transmission. However, most of Sahelian Africa, as well as East Africa, parts of Southern Africa, most of India, as well as most of Southeast Asia and
essentially all of South America have high probabilities of interruption at this control level. Note that local conditions (within a given pixel) may be
more or less favorable to transmission than the per-pixel averages shown here, and so these maps are most applicable for regional or country-level
planning, rather than local-level control efforts. Microenvironments or ‘hotspots’ might require additional interventions and/or greater treatment
coverage than the per-pixel average [67]. Data collection sites used to construct the maps are reported in [45]. A partial database of the actual site
locations and the measured levels of malaria endemicity can be found on the Malaria Atlas Project (MAP) website: www.map.ox.ac.uk.
doi:10.1371/journal.pcbi.1003434.g004
Figure 5. Map of the predicted probabilities that five-fold reductions will interrupt transmission in Southeast Asia. The predicted
probabilities that a control effort with a five-fold reduction would interrupt transmission are shown for Southeast Asia, using the same masking of
high transmission areas (R0.10) and mapping assumptions as for Figure 4. Areas that appear to be uniform may have small-scale heterogeneities in
transmission that are beyond the scale of this map. Map pixel size is 5 km2.
doi:10.1371/journal.pcbi.1003434.g005
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parasite life-cycle, then there is little difference in the benefits of ACTs
versus ACTs+PQ in terms of transmission reductions. Both regimens
are extremely effective at stopping onward transmission, with many
fold greater benefits versus purely schizonticidal treatments that act
only upon asexual blood stage parasites. Third, the proportion of
individuals receiving treatment has a major impact on reductions in
transmission (Figure 3B). In Tables 1 and 2 our effect size
calculations assumed 100% coverage. Because untreated individuals
are so much more infectious than treated individuals, leaving even a
few individuals untreated drastically reduces the effectiveness of a
control program.
We can put these fold-reductions in context using our maps of
transmission reductions necessary for elimination. Figure 4
illustrates a worldwide map of the probabilities that a five-fold
reduction in transmission would interrupt the spread of malaria. In
this map the pixel size is 5 km2. Because our model is most
applicable in regions of relatively low transmission, we masked out
the regions where R0, the basic reproductive number, is predicted
to be greater than 10 (with a probability exceeding 50%). Higher
transmission regions are more difficult to model, given the
complex interactions of immunity, superinfection, and control.
As can be seen from the map, many areas of Africa have such
intense transmission that R0 exceeds 10, and we cannot say how
transmission might be affected by the use of drugs in such areas.
However, examining the map, one can visualize many regions
of Africa, including the Sahel, most of East Africa, and parts of
Southern Africa, where elimination would appear possible with a
five-fold reduction in transmission. Further, much of India and
Southeast Asia have low enough transmission that elimination
would be possible at this level of control. Prospects for elimination
in Myanmar and southern Thailand, however, do not appear to be
favorable. Figure 5 provides a zoomed-in view of the probabilities
of malaria elimination with an effect size of five, focusing on
Southeast Asia. Table 3 provides a quantification of the
populations at risk both worldwide and in Southeast Asia, as well
as the populations where elimination is possible at different levels
of control. Worldwide, regions where malaria can be interrupted
with five-fold reductions contain 74% of the population at risk; in
Southeast Asia regions that can interrupt transmission with five-
fold reductions harbor 91% of the population at risk.
Given these maps and quantifications of populations at risk, we
can apply our modeling results to determine the percentage of the
population that needs to be treated promptly with antimalarials to
interrupt transmission in various areas. Figure 3B illustrates the
relationship between treatment coverage with different antimalar-
ials and the resulting fold reductions in transmission, assuming the
Jeffery-Eyles gametocyte density-to-infectivity relationship (used to
calculate the needed treatment coverage levels below). To achieve
a five-fold reduction in transmission, approximately 81% of the
total infected population would need to be treated with ACTs or
ACTs+PQ. As a comparison, achieving this fold reduction with
CQ (with weak activity against early-stage gametocytes) or a
schizonticide (with no gametocytocidal activity) would require
treatment coverage of ,86% and ,96% respectively. To achieve
a six-fold reduction in transmission, approximately 84% of the
total infected population would need to be treated with ACTs or
ACTs+PQ (illustrated in Figure 3B). Our modeling thus suggests
that the addition of PQ to an ACT would provide almost
negligible benefits at these levels of coverage, reducing the fraction
of the population needing to be treated by less than 1% versus
treatment with ACTs alone that already provide quite potent
gametocytocidal activity (Figure 3B).
Combining the maps and the within-host modeling results based
on our JE parameterization, we thus estimate that promptly
treating ,81% of the total infected population with ACTs and/or
ACTs+PQ would interrupt transmission in areas covering 91% of
the population in Southeast Asia. These coverage rates are for the
infected population as a whole, regardless of whether individuals
are symptomatic or not. In a study conducted in a region of
western Thailand with low and seasonal transmission, most
infections (87%) were found to be symptomatic [48]. In
experimental challenge studies among human volunteers, all
subjects displayed some degree of symptoms [49].
If we take the former proportion (87%) as the percentage of the
infected population that is symptomatic, then 93% of the
symptomatic population would need to be treated with ACTs
and/or ACTs+PQ to achieve interruption in the areas of Figure 5
based on the predicted five-fold reduction; the percentage rises to
97% to achieve six-fold reductions. Thus, it is possible that treating
only symptomatic individuals may be sufficient to eliminate
transmission throughout most of Southeast Asia. Almost all of
these individuals, however, would need to be reached with
treatment (either through a public campaign or private sector
provisioning or a combination of both) in order to interrupt
transmission, using drugs alone. Our result that prospects for
malaria elimination are favorable for most of Southeast Asia is
supported by two other studies that also find that elimination
efforts are feasible using antimalarials in this region [50,51].
Figures S4 and S5 illustrate the probabilities assuming control
interventions with two-fold and ten-fold reductions, respectively.
At the two-fold level, much of central Thailand can interrupt
transmission, but there are significant portions of Myanmar,
Cambodia, Southern Laos, and Southern Thailand where
elimination is not likely. At the ten-fold level, there are small
pockets in Southern Thailand as well as large areas in Myanmar
where interruption is still not likely.
These estimates may be somewhat optimistic because we are
using only the JE density-to-infectivity relationship when calculat-
ing the infectivity of treated individuals. As we are focusing on low
transmission areas, this assumption seems reasonable (the JE
relationship was derived from individuals with no prior infections).
However, if we take the mean of the JE and CG relationships for
treated individuals, then we predict that it would require treating
85.5% of the total population, or 98.3% of symptomatic patients
with ACTs to achieve a five-fold reduction (85.0% of the total or
97.7% of symptomatic patients with ACTs+PQ). Further, we find
that it is not possible to achieve a six-fold reduction only treating
symptomatic individuals with either the ACTs or the ACTs+PQ
modeled here, assuming the mean of the JE and CG relationships
for treated individuals. Thus, the assumed density-to-infectivity
relationship has a large effect on the calculated effectiveness of
control programs.
We note that our maps predict the levels of control necessary to
interrupt transmission at the per-pixel level (5 km2), incorporating
uncertainty analysis. These average reductions needed to interrupt
malaria transmission are not at the per-village or per-household
level. Hotspots of transmission will need to be identified and
treated in order to achieve elimination in a given region. The
uncertainty for each pixel takes into account this heterogeneity to
some degree, but nevertheless caution is advised before using these
maps for local-scale planning. We would suggest our maps be used
to guide elimination planning at a regional or national level; for
elimination planning at a district or city level more intensive
surveillance will likely be needed.
If we consider the timelines to elimination, the narrower the
margin by which the effect size exceeds the threshold for
elimination, the longer elimination will take, as population-wide
transmission will decay more slowly [46]. Conversely, the higher
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the proportion of individuals above the needed threshold, the
faster elimination will be achieved [46]. We do not compute the
quantitative benefits of mass drug administration here, and instead
focus on individual-level treatment. However, we would qualita-
tively expect that mass drug administration may provide a benefit
to elimination efforts by speeding an area toward faster
elimination, assuming that the critical level of coverage can be
reached (i.e. the RC of the region drops to below 1). Once an area
has eliminated malaria, the costs of maintaining elimination may
be less than those needed to achieve elimination in the first place,
though more research is needed on strategies to maintain
elimination in previously endemic areas [7].
In areas where antimalarials are predicted to be insufficient to
achieve elimination, other interventions may be included in
control efforts to increase the effect size of the combined control
effort. The combined effect size is simply the product of both
component interventions. For example, if the coverage level with
antimalarials reduces transmission by three-fold and distribution of
bed nets reduces transmission another three-fold, the combined
effects are a nine-fold reduction in transmission (as long as there
are no antagonistic interactions between the two efforts). Thus,
high fold-reductions can be achieved by bundling interventions.
While we do not compute the effect sizes of other interventions
here, the results in this paper can be combined with other
modeling efforts for the purposes of an integrated elimination
effort.
Given these conclusions, serious efforts to eliminate malaria will
require extensive planning and sustained support [6]. We note the
encouraging prediction that high coverage (at least 81–85% of
total infections, corresponding to an estimated 93–98% of
symptomatic infections) with ACTs that act against P. falciparum
asexual, sexual, and mosquito stages might suffice to interrupt
transmission throughout most of Southeast Asia, especially if
complimented by insecticide-treated bed net distribution to reduce
population infectivity. We also note that the addition of a single
dose of a purely gametocytocidal drug such as PQ to ACTs can
reduce onward transmission slightly. However, the focus of control
efforts should be on maintaining a high level of treatment
coverage. Based on our modeling, PQ and similarly gametocyto-
cidal therapies added to ACTs do not appear to be a magic bullet
ensuring elimination and add only nominally to the transmission
reductions achievable with ACTs that act against the various
parasite stages at feasible levels of coverage.
Efforts are ongoing to utilize our model to predict the effects of
possible emerging artemisinin resistance, which threatens existing
ACT control strategies [10,52,53]. Additional modeling is also
required to delineate better what measures beyond expanded
ACT and insecticide-treated bed net coverage would help reduce




Our recently reported within-host mathematical model [23] was
utilized to simulate asexual and sexual blood stage parasite
densities over time in untreated and treated individuals. This
model reproduces the range of observed parasite densities among
individuals undergoing malaria therapy, wherein adult males with
tertiary syphilis (and no acquired immunity to malaria) were
infected with various strains of P. falciparum to induce a fever in
order to clear the syphilis [29,54–56]. Our model uses a
combination of parasite antigenic variation and host immune
responses to reproduce the observed range of responses in these
patients. The model calculates the density of asexual parasites
every two days and uses log-linear interpolation to generate daily
counts. The model also calculates the daily human-to-mosquito
infectivity using gametocyte density-to-infectivity relationships
derived from mosquito feeding studies on human volunteers
[23]. The source code for our model is provided in Dataset S1
(see SI). We note that our modeling uses discrete-time difference
equations rather than a continuous time model, to calculate both
asexual densities and gametocyte densities over time. We chose the
former, as the calculation of gametocyte densities from asexual
densities is difficult with a continuous-time model because
gametocyte densities are a function of weighted cumulative
asexual densities and are highly stochastic. For a thorough
description, we refer to [57].
We also note that an insightful report by Kay and Hastings [58],
building on earlier work from this group [59], simulated the
concentrations of both artemisinin derivatives and ACT partner
drugs using compartmental PK/PD modeling. These authors also
simulated the killing effects of these drugs against asexual parasites
assuming Michaelis-Menten dose-response functions (which are
similar to the Hill functions used here). These authors focused on
the effects of emerging artemisinin resistance and provided
substantial data on artemisinin PK/PD properties. Our two
studies differ in that we simulated parasite densities daily and so we
did not explicitly model artemisinin PK values because of the short
half-lives of the artemisinins. Further, our stochastic difference
equation model of within-host parasite growth and immune
response was calibrated to match the range of variation in the
malaria therapy data [23]. We also modeled the effects of drugs
against asexual, sexual, and mosquito stages of development.
Thus, The Kay and Hastings study [58] is a representation of the
effects of drugs against asexual stages incorporating resistance,
whereas our study focused on the effects of drugs on total human
malarial transmission. Importantly, their simulations predict that
the spread of ART resistance would result in a potentially rapid
decline in ACT effectiveness. In future studies, we plan to
investigate the effect of ART resistance on effect sizes and how this
would impact the required treatment coverage to drive the RC to
below 1 in low-transmission settings.
Antimalarial drug pharmacokinetics
PK modeling was used to simulate the concentrations of
antimalarial drugs after uptake. The concentrations of CQ and its
active metabolite, monodesethyl-chloroquine (mdCQ), were sim-
ulated using a non-compartmental model parameterized with data
from Papua New Guinean children [60]. For LMF, a two-
compartmental model was developed from plasma concentration
data from the treatment of uncomplicated individuals in western
Thailand (Mae La) [61]. For MFQ, a non-compartmental model
was developed that incorporated data from two studies, one in
Thailand [62] and the other in Peru [63] (the Peruvian study used
whole blood concentrations, rather than plasma). The plasma
concentrations of the artemisinins were not modeled, although
such data exist [62]. This is because the half-lives of the
artemisinins are so short (,1–3 hr) that effective concentrations
are gone within one day after uptake [62]. A full description of the
PK modeling is provided in the SI.
Drug pharmacodynamics against asexual parasites
The dose-response effect of antimalarials against asexual
parasites was assumed to follow the commonly used ‘Hill function’
[64], a four-parameter dose-response function: K(x)~ a{bð Þ
.
1z x=cð Þd
 Þzb, where a is set to 0, b is set to 1, c is what we
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term the EC50, d is the Hill slope, and x is the plasma
concentration of the drug. The Hill function dose-response curve
type was chosen because this function type was utilized by both of
the references that provided in vivo EC50 values for MFQ [65,66],
and because many of the in vitro studies using CQ and LMF used
Hill dose-response relationships to model the effects of drugs
against asexual blood stage parasites. Because each drug has a
characteristic maximum inhibitory effect, this dose-response
function was scaled by the maximum parasite reduction ratio
(PRR) for each drug. To determine the effect on asexual parasites
of a drug concentration on a given day t of modeling, the asexual
parasite densities from day t-1 were used as inputs into the within-
host model. The predicted densities on day t were then calculated,





:K xð Þ over day t was then subtracted from the
within-host simulations after appropriate log transformation to
calculate the end of day asexual parasite densities, incorporating
the effects of host immune responses, parasite growth, and drug
concentrations. These densities were then used to calculate the
asexual parasite densities on day t+1, and so on until the end of the
simulation time. A full description of the PD modeling against
asexual blood stages is provided in the SI.
Drug pharmacodynamics against gametocytes
The dose-response effect of antimalarials against gametocytes
was assumed to follow a binary model, where antimalarials act
against gametocytes only if drug concentrations are above a
certain drug-specific threshold. This binary model was adopted
because of the current paucity of dose-response data against
gametocytes, as compared to asexual blood stage parasites where
the many data sets permit the use of Hill slopes to define dose-
response relationships. The threshold for gametocyte activity was
chosen to be the in vitro IC50 against asexual blood stage parasites
scaled by a factor of five [21]. For CQ, LMF, and MFQ, this value
is 40, 174, and 322 ng/ml, respectively (SI). To determine the
stage-specific gametocytocidal effects of drugs, the within-host
malaria model was first run assuming treatment with a purely
schizonticidal combination therapy. The post-treatment gameto-
cyte clearance curves from these simulations were then compared
to clearance curves from field studies using SP [28,30–38] to
validate the model outputs. In separate simulations, we assumed
that individuals were treated with a combination that was weakly
gametocytocidal, and these results were compared to field data
from CQ trials [28,30–33] to choose a drug parameterization. We
also performed simulations assuming treatment with a stronger
gametocytocidal combination, and modeled our parameters by
comparing these results with ACT field trial data [28,30–32,34–
36,38]. Finally, we simulated treatment with a stronger gameto-
cytocidal combination paired with a third highly gametocytocidal
drug, and compared these results to ACT+PQ field data
[35,36,38] to parameterize this combination. Outputs from
modeled drug parameterizations that were consistent with
observed trends were considered representative of that type of
treatment. A full description of the process of model parameter-
ization of antimalarial effects against gametocytes is provided in
the SI.
Drug pharmacodynamics against mosquito-stage
parasites
Once the ensembles of gametocyte densities after treatment had
been generated for various drug combinations, we used two
different gametocyte density-to-infectivity relationships (‘Jeffery-
Eyles’ and ‘Carter & Graves’) to translate the daily gametocyte
densities into predicted human-to-mosquito infectivities [23].
These modeled daily infectivities were then compared to field
studies in which mosquitoes were fed on human volunteers after
treatment. For the effects of a single dose of PQ on drug
transmission, we assumed that the first three days post-treatment
were non-infectious (including the day of treatment). For the
effects of partner drugs with longer half-lives that are active against
sexual-stage parasites for longer periods (LMF, MFQ), we scaled
the area under the infectivity curve (AUIC).
Analysis of model uncertainty
To quantify the uncertainty associated with our predictions, we
utilized an ensemble modeling approach [40,41]. In ensemble
modeling, various scenarios are simulated to illustrate the effects of
changing assumptions of model outputs. Ensemble modeling is
especially appropriate when insufficient or conflicting data exist to
determine the relative likelihoods of the possible scenarios. For our
ensembles, we used different sets of assumptions about the stage-
specific effects of drugs against gametocytes and the type of
gametocyte density-to-infectivity relationship to map out the
uncertainties associated with our best-estimate predictions of the
effects of drugs on transmission.
Supporting Information
Dataset S1 Text of source code for model (final_mo-
del.rtf).
(RTF)
Figure S1 Post-treatment gametocyte prevalences from
field studies. The graphs show gametocyte prevalences of field
populations after antimalarial treatment. Gametocyte positivity
was assessed using microscopy (threshold ,5–10 gametocytes per
mL blood). The notation (‘2 Day 0’) indicates that only individuals
who were gametocyte negative at admission were included in the
study. Field notes include the location of study and subset of
population treated. All study curves represent mean population
values linearly interpolated from measured prevalences. (A) The
percentage of individuals positive for gametocytes after treatment
with sulfadoxine-pyrimethamine (SP) [28,30,33]. The pattern after
SP treatment can be described as an inverted-V: few mature
gametocytes were present at treatment because treatment was
relatively prompt and some studies excluded gametocyte carriers
at admission. A peak in prevalence was caused by sequestered
gametocytes emerging into the blood stream. The peak gradually
declined as the immune system cleared gametocytes from the
blood. (B) Gametocyte prevalences after treatment with chloro-
quine (CQ) or amodiaquine (AQ) (sometimes in combination with
SP) [28,30–33]. (C) Gametocyte prevalences after treatment with
various artemisinin-based combination therapies (ACTs): (arte-
mether-lumefantrine, AL), (artesunate, A1, A3, AS), (artesunate-
mefloquine, AM), (dihydroartemisinin-piperaquine, DHP) [28,30–
32,34–36,38]. (D) Gametocyte prevalences after treatment with
ACTs plus primaquine (PQ) [35,36,38].
(PDF)
Figure S2 Comparison of modeled post-treatment ga-
metocyte prevalences to field study data. The post-
treatment gametocyte prevalences from Figure S1 were averaged
to create a set of target data to parameterize the modeled effects of
antimalarials on transmission. (A) The mean of the field data after
treatment with sulfadoxine-pyrimethamine (SP) [28,30,33] is
illustrated by the red line and the range of observed responses
are depicted in light blue. The modeled gametocyte carriage
curves are shown in black and green. All model treatment was
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assumed to start 5 days after the first onset of fever, consistent with
average behavior from field studies [34,38]. All model outputs
represent the mean of 1,000 runs. The solid black line illustrates
modeled gametocyte carriage among untreated individuals; the
dashed black line illustrates modeled clearance in untreated
individuals among gametocyte negatives at admission (‘- Day 0’).
Modeled gametocyte clearance in untreated individuals is
mediated only by immune processes as described in [23]. The
solid green line depicts modeled gametocyte prevalence after
treatment with a schizonticidal combination therapy (i.e. a short-
lived component that rapidly kills asexual parasites and a longer-
lived one that is less potent; neither are assumed to affect
gametocytes); the dashed green line depicts modeled gametocyte
carriage after schizonticidal treatment, including only gametocyte
negative individuals at treatment (‘- Day 0’). (B) Gametocyte
prevalences after treatment with chloroquine (CQ) or amodia-
quine (AQ) (sometimes in combination with SP) [28,30–33]; mean
values are illustrated in red, range in blue. Modeled gametocyte
prevalences are also provided. Model prevalences assume
treatment with a combination of drugs (short-lived and long-lived)
that kill asexual parasites but only affect early stage gametocytes.
Mild, moderate (2 being stronger than 1), and strong model
outputs vary in the assumed intensity of early stage gametocyte
killing. (C) Gametocyte prevalences after treatment with various
artemisinin-based combination therapies (ACTs) [28,30–32,34–
36,38]; mean values are in red and the range is illustrated in blue.
Model data illustrate treatment with a combination of drugs, a
shorter-lived one that kills both early and late stage gametocytes
and a longer-lived partner that only kills early stages. Model
outputs vary in their assumed gametocyte killing strengths. The
curve labeled ‘no late stage effects’ illustrates the effects of a
combination that has no effect on gametocytes aged .13 days old.
(D) The same data as in (C) are illustrated with the exception that
two ACT field studies were removed from the field data curves
because of potentially confounding drug resistance effects
(CQ+AS, [31] and SP+AS, [35]). (E) Gametocyte prevalences
after treatment with ACTs plus primaquine (PQ) [35,36,38]; the
red line indicates the mean of field studies; the range of studies is
shown in blue. Model outputs assume treatment with three drugs:
a short-lived drug that kills early and late stage gametocytes, a
long-lived partner that kills late stage gametocytes only (these first
two drugs were parameterized from the ACT field data, using the
‘mild’ parameterization), and a second short-lived partner drug
that strongly kills both early and late stage gametocytes. The
designation of,day 0. or,day 2. refers to the numbers of days
that single dose PQ was delayed after initiating ACT treatment
(i.e. simultaneously or 2 days after).
(PDF)
Figure S3 Infectivity to mosquitoes after treatment.
These graphs illustrate the probability that a human will infect a
mosquito following antimalarial treatment. Infectivity is defined
as the probability that a mosquito bite will produce oocysts.
Field study data are indicated with markers; model outputs are
indicated by curves. All model outputs represent the mean of
1,000 runs; treatment was assumed to begin 5 days after first
fever. Field markers represent the mean from a set of mosquito
feedings. Model output curve coloring is taken from Figure S1.
Two different gametocyte density-to-infectivity relationships
were used to model infectivity: Jeffery-Eyles (in bold; JE) and
Carter & Graves (CG) [23]. Some field and model data included
only gametocyte negative individuals at admission, as indicated
by (‘Day 0 2’); others included all individuals (‘Day 0 +/2’). (A)
Field data post-treatment with SP (sulfadoxine-pyrimethamine)
or SP plus amodiaquine (AQ) [28]. The modeled outputs are
from simulations approximating the effects of chloroquine (CQ)
treatment. Field-measured infectivity after SP treatment resem-
bles that of modeled CQ treatment, even though gametocyte
densities after SP treatment were much higher than after CQ.
The discrepancy is explained in part by evidence that SP acts
against the mosquito stages of development, thus reducing the
human-to-mosquito infectivity for given levels of gametocytemia
[68–70]. (B) Field-measured infectivity after treatment with CQ,
SP, or CQ+SP [30–33]. Model outputs were normalized to
remove simulated individuals positive at treatment. The JE
parameterization is more consistent with field data, although it is
unclear how infectious individuals were 0–3 days post-treatment.
(C) Field-measured infectivity [28,37] and modeled outputs after
treatment with artemisinin-based combination therapies (ACTs),
including only individuals that were gametocyte negative at
admission. (D) Field-measured infectivity [30–32] and modeled
outputs after treatment with artemisinin-based combination
therapies (ACTs), including all treated patients. The JE
parameterization is more consistent with field data, at least
after the initial period of infection. (E) Field-measured infectivity
after treatment with ACTs [28,37]; modeled infectivity is for
ACTs plus primaquine (ACT+PQ). The lack of field infectivity
data for the ACT+PQ combination treatment precludes direct
comparison, but the ACT-treated field data is provided for
reference. (F) Field-measured infectivity after treatment with
ACTs, excluding individuals positive for gametocytes [30–32];
modeled infectivity is for ACT+PQ, also after exclusion. The JE
parameterization produced infections that are infectious only at
an extremely low level.
(PDF)
Figure S4 Maps of the predicted probabilities that a
two-fold effect size will interrupt malaria transmission.
The upper map shows the predicted probabilities that a two-fold
reduction in transmission (‘two-fold effect size’) would interrupt
malaria transmission over a given pixel. Map pixel size is 5 km2. In
order to interrupt malaria transmission in a given area, the basic
reproductive number for malaria under control (RC) needs to be
reduced below 1. Probabilities for each pixel are calculated
according to Bayesian posterior estimates of uncertainty (45).
Probabilities have been binned into six categories for clarity. Areas
with high transmission (R0.10) are masked because our model
results are applicable to regions of relatively lower transmission.
Note that local conditions (within a given pixel) may be more or
less favorable to transmission than the per-pixel averages shown
here, and so these maps are most applicable for regional or
country-level planning, rather than local-level control efforts.
Microenvironments or ‘hotspots’ might require additional inter-
ventions and/or greater treatment coverage than the pixel average
[67]. The lower map inset illustrates the predicted probabilities
that a control effort with a two-fold reduction would interrupt
transmission in Southeast Asia, using the same masking of high
transmission areas (R0.10) and mapping assumptions as for the
upper map. Areas that appear to be uniform may have small-scale
heterogeneities in transmission that are beyond the scale of this
map.
(PDF)
Figure S5 Maps of the predicted probabilities that a
ten-fold effect size will interrupt malaria transmission.
The upper and lower maps are illustrated as per Figure S4,
except that Figure S5 shows the predicted probabilities that a ten-
fold reduction in transmission (‘ten-fold effect size’) would
interrupt malaria transmission over a given pixel (size is 5 km2).
(PDF)
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Text S1 Pharmacokinetic and pharmacodynamic equa-
tions and distributions [71–90].
(PDF)
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